SCHEMBL3093467

SCHEMBL3093467

NC(=O)Oc1ccccc1-c1nc2ccc(OC(c3c(Cl)cccc3Cl)C(F)(F)F)cc2s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.40
MAPT P10636 3/20 0.35
TP53 P04637 2/20 0.35
CA2 P00918 1/20 0.35
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CSNK1D P48730 2/20 0.34
GHSR Q92847 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3099130 0.87 DYRK1A (0.43) DYRK1AMAPTTP53CA2MEN1
SCHEMBL3093478 0.86 APP (0.41) MAPTTP53MEN1NPC1ALDH1A1
SCHEMBL3099171 0.85 DYRK1A (0.42) DYRK1AMAPTTP53CA2MEN1
SCHEMBL3102181 0.82 DYRK1A (0.42) DYRK1AMAPTRAB9A
SCHEMBL3108703 0.81 MET (0.51)
SCHEMBL3093456 0.80 NR1H4 (0.46) DYRK1AMAPTTP53CA2NPC1
SCHEMBL3104751 0.80 DYRK1A (0.43) DYRK1AMAPTTP53CA2MEN1
SCHEMBL3104156 0.79 MET (0.43) DYRK1AMAPTTP53
SCHEMBL3093433 0.79 DYRK1A (0.42) DYRK1ARAB9A
SCHEMBL3098700 0.79 NR1H4 (0.43) DYRK1ATP53MEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 DYRK1A 979/4885MAPT 2894/4885TP53 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.